The Human Genetics and Microbiome Core will be co-directed by Mark Daly and Curtis Huttenhower. The services offered within this core are composed of a suite of services from more routine and heavily used molecular biology services (e.g., whole plasmid DNA sequencing) to computationally complex tools to analyze the role of genetics and the microbiome in IBD (e.g., statistical association testing between host genotypes and microbiome).Central to all services are formal and informal end-to-end consultations and training on experimental design, data generation, and bioinformatics analysis. A team of bioinformaticists and software developers with in-depth expertise are available within the Core to provide collaborative capacity for analysis of genetics, microbiome, and/or functional data This core will be a major connection point for clinicians and basic researchers, as it operates at the intersection between patient samples and basic research techniques.
The specific aims of Human Genetics and Microbiome Core are divided according to its two themes. For genetics, the Core will (1) facilitate the application of advanced experimental platforms for genetics, genomics, and high-throughput data analysis to discovery efforts relevant to IBD; (2) provide a centralized facility and personnel for performing state-of-the-art recombinant and PCR-based DNA procedures and RNA interference and provide cost-effective and high- quality molecular biology reagents and services; and (3) provide a resource for disseminating a wide range of molecular biology, genetic, and bioinformatics technologies. For microbiome services, the Core will (1) provide an end-to-end sampling and multi?omic profiling system for the host and microbiota in IBD and gastrointestinal disease; (2) provide computational resources to analyze and interpret the microbiome; and (3) develop cutting-edge solutions in microbiome research that will drive therapeutic discovery.
|Gevers, Dirk; Kugathasan, Subra; Knights, Dan et al. (2017) A Microbiome Foundation for the Study of Crohn's Disease. Cell Host Microbe 21:301-304|
|Molinie, Benoit; Giallourakis, Cosmas C (2017) Genome-Wide Location Analyses of N6-Methyladenosine Modifications (m6A-Seq). Methods Mol Biol 1562:45-53|
|Schwerd, Tobias; Pandey, Sumeet; Yang, Huei-Ting et al. (2017) Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. Gut 66:1060-1073|
|Maehara, Takashi; Mattoo, Hamid; Ohta, Miho et al. (2017) Lesional CD4+ IFN-?+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann Rheum Dis 76:377-385|
|Jung, Keehoon; Heishi, Takahiro; Khan, Omar F et al. (2017) Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest 127:3039-3051|
|Rooks, Michelle G; Veiga, Patrick; Reeves, Analise Z et al. (2017) QseC inhibition as an antivirulence approach for colitis-associated bacteria. Proc Natl Acad Sci U S A 114:142-147|
|Miyabe, Chie; Miyabe, Yoshishige; Strle, Klemen et al. (2017) An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis 76:898-905|
|Ananthakrishnan, Ashwin N; Luo, Chengwei; Yajnik, Vijay et al. (2017) Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe 21:603-610.e3|
|Canali, Susanna; Zumbrennen-Bullough, Kimberly B; Core, Amanda B et al. (2017) Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 129:405-414|
|Ananthakrishnan, A N; Sakuraba, A; Barnes, E L et al. (2017) The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther 46:162-168|
Showing the most recent 10 out of 1056 publications